GENEVA JOHNSON: Open Payments
NPI 1245004506 · SPARKS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$537 in 16 payments from 10 companies in 2025. Trend: 2023 $113 · 2024 $151 · 2025 $537
Food & beverage: $537
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 2 | $161 |
| Neurocrine BioSciences, Inc. | 1 | $118 |
| ABBVIE INC. | 3 | $73 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $40 |
| PFIZER INC. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Amgen Inc. | 1 | $27 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
Products named: UPTRAVI, INGREZZA, VRAYLAR, JOURNAVX, OPSUMIT, NURTEC ODT, CAPLYTA, KRYSTEXXA.
Industry payments across NV — which companies pay providers there.
